Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)—A Randomized Controlled Trial

Anna Obermayer, Norbert J. Tripolt, Peter N. Pferschy, Harald Kojzar, Faisal Aziz, Alexander Muller, Markus Schauer, Abderrahim Oulhaj, Felix Aberer, Caren Sourij, Hansjorg Habisch, Tobias Madl, Thomas Pieber, Barbara Obermayer-Pietsch, Vanessa Stadlbauer, Harald Sourij

    Research output: Contribution to journalArticlepeer-review

    27 Scopus citations

    Abstract

    OBJECTIVE To investigate the safety and feasibility of 3 nonconsecutive days of intermittent fasting (IF) per week over 12 weeks in participants with insulin-treated type 2 diabetes. RESEARCH DESIGN AND METHODS Forty-six people were randomized to an IF or control group. Dietary counseling and continuous glucose monitoring was provided. Coprimary end points were the change in HbA1c from baseline to 12 weeks and a composite end point (weight reduction ‡2%, insulin dose reduction ‡10%, and HbA1c reduction ‡3 mmol/mol). RESULTS The IF group showed a significant HbA1c reduction (27.3 ± 12.0 mmol/mol) compared with the control group (0.1 ± 6.1 mmol/mol) over 12 weeks (P = 0.012). The coprimary end point was achieved by 8 people in the IF and none in the control group (P < 0.001). No severe hypoglycemia occurred. CONCLUSIONS IF is a safe and feasible dietary option to ameliorate glycemic control while reduc-ing total daily insulin dose and body weight in insulin-treated people with type 2 diabetes.

    Original languageBritish English
    Pages (from-to)463-468
    Number of pages6
    JournalDiabetes Care
    Volume46
    Issue number2
    DOIs
    StatePublished - Feb 2023

    Fingerprint

    Dive into the research topics of 'Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)—A Randomized Controlled Trial'. Together they form a unique fingerprint.

    Cite this